Clinical trials: Levodopa
Macula; Degeneration, Retina
Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)
This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD.
- Trial name
- NCT03197493
- Testing
- carbidopa-levodopa 25-100 mg
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169479
- Testing
- BIA 9-1067, Sinemet® 100/25
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Cocaine Dependence
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
Cocaine dependence is a major public health problem and the development of a treatment for this disorder is a priority. To date, treatment interventions based on positive incentive principles have shown the strongest effects for…
- Trial name
- NCT00713583
- Testing
- levodopa, Cognitive Behavioral Therapy, Contingency Management
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- The University of Texas Health Science Center, Houston
Parkinson's Disease
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
- Trial name
- NCT00199381
- Testing
- Istradefylline
- Where
- United States
- Volunteers
- 504 people
- Sponsor
- Kyowa Kirin, Inc.
Cocaine Dependence
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
The proposed study will look at cocaine dependent individuals and will consist of three consecutive phases: 1) the 2-week outpatient lead-in phase during which behavioral therapy will be administered; 2) the 15-21 day inpatient…
- Trial name
- COST (NCT01468012)
- Testing
- levodopa carbidopa and entacapone (LCE)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Advanced Parkinson's Disease
A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease
The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.
- Trial name
- NCT01736176
- Testing
- Levodopa-Carbidopa Intestinal Gel, Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J), Levodopa-carbidopa Immediate Release (LC-IR) Tablets
- Volunteers
- 39 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease (PD)
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg…
- Trial name
- NCT02170376
- Testing
- BIA 9-1067, Entacapone, Levodopa/carbidopa
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Dyskinesia, Levodopa Induced Dyskinesia (LID)
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
- Trial name
- EASE LID (NCT02136914)
- Testing
- ADS-5102
- Where
- 46 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Parkinson's Disease
Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients
The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated with levodopa/dopa-decarboxylase inhibitor.
- Trial name
- NCT01568047
- Testing
- BIA 9-1067, Levodopa/Carbidopa, Levodopa/Benzerazide
- Where
- 7 sites in Romania, Ukraine
- Volunteers
- 40 people
- Sponsor
- Bial - Portela C S.A.
Dyskinesia, Parkinson's Disease
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with…
- Trial name
- LID in PD (NCT01767129)
- Testing
- AVP-923-45
- Where
- 3 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Avanir Pharmaceuticals
Parkinson's Disease
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
- Trial name
- ANDANTE (NCT01049984)
- Testing
- Rasagiline
- Where
- 58 sites in United States
- Volunteers
- 328 people
- Sponsor
- Teva Neuroscience, Inc.
Idiopathic Parkinson Disease
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
Phase 3, international, multicenter, open-label 12 month safety study.
- Trial name
- NCT03051607
- Testing
- Tozadenant
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Biotie Therapies Inc.
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Major Depressive Disorder, Dysthymia
A Study of L-DOPA for Depression and Slowing in Older Adults
Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Decreased Processing Speed
- Trial name
- NCT02744391
- Testing
- Levodopa
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- New York State Psychiatric Institute